Sort
51,593 grants matching “hepatitis”
Mechanisms of Alcoholic Liver Disease
$600,071Bin Gao · Alcohol Abuse And Alcoholism · Z01 · FY2007 · AA
Telomerase in Development, Senescence and Neoplasia
$600,026Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · R37 · FY2014 · CA
Body Composition & REE Responses to Bariatric Surgeries
$600,019Dympna Gallagher · St. Luke'S-Roosevelt Inst For Hlth Scis · R01 · FY2012 · DK
Acquisition of Detector for JEOL 3200 FSC Electron Microscope
$600,000Bridget Olivia Carragher · New York Structural Biology Center · S10 · FY2015 · OD
Mechanisms of Transition Metal Catalyzed Reactions in Hydrocarbons
$600,000Robert H Grubbs · California Institute Of Technology · · FY2015 · MPS
CAREER: Simultaneous Single-Molecule Manipulation and Visualization for Study of ATP Coupling to Base Pair Unzipping
$600,000Wei Cheng · Regents Of The University Of Michigan - Ann Arbor · · FY2012 · MPS
MRI-Compatible PET Insert for Small Bore Scanner
$600,000Peter D Caravan · Massachusetts General Hospital · S10 · FY2017 · OD
Console Upgrade for 4.7T PET-MRI Preclinical Scanner
$600,000Christian T Farrar · Massachusetts General Hospital · S10 · FY2023 · OD
Racial Difference in HCV-Host Interactions and Response
$600,000University Of Tennessee Health Sci Ctr · U19 · FY2005 · AI
Upgrade the 14T Ultrahigh Field Horizontal MR Scanner for Rodent and ex-vivo Imaging
$600,000Bruce R Rosen · Massachusetts General Hospital · S10 · FY2021 · OD
LTQ-Orbitrap Velos instrument
$600,000Belinda Belle Willard · Cleveland Clinic Lerner Com-Cwru · S10 · FY2011 · RR
BioLINCC
$599,990Carol Giffen · Information Management Services, Inc. · N01 · FY2010 · HL
B-SMART - Broadly neutralizing antibodies for SaRNA Mediated Antiviral Response Therapy
$599,989Mark Lee Harlow · Lynntech, Inc. · N43 · FY2025 · AI
Characterization Methodologies & Proteomics to Assess Carbon Nanotube Exposure
$599,981Frank A Witzmann · Indiana University Indianapolis · RC2 · FY2009 · ES
Three-dimensional organoid culture using the CellRaft microwell technology
$599,959Jessica Hartman · Cell Microsystems, Inc. · R44 · FY2021 · ES
Thrombocytopoiesis in Diabetes: Role of Damage Associated Molecular Patterns
$599,907Prabhakara Reddy Nagareddy · Ohio State University · R01 · FY2021 · HL
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** CONTAMINATION OF READY-TO-EAT (RTE) FOODS WITH PATHOGENIC MICROORGANISMS CONTINUE TO POSE A SERIOUS RISK TO PUBLIC HEALTH. FOR YEARS, MULTIPLE CASES OF LARGE-SCALE OUTBREAKS AND RECALLS DUE TO ENVIRONMENTAL CONTAMINATION WITH SALMONELLA ENTERICA AND LISTERIA MONOCYTOGENES HAVE BEEN REPORTED. REINFORCEMENT OF CURRENT GOOD MANUFACTURING PRACTICES, IMPLEMENTATION OF NEW FSMA REGULATIONS AND DEPLOYMENT OF NEW INTERVENTION STRATEGIES HAVE YET TO RESULT IN A MARKED REDUCTION IN THE INCIDENCE OF RECALLS AND OUTBREAKS; IT IS THEN CRITICAL TO EXPLORE NOVEL TECHNOLOGICAL STRATEGIES. THE ENVIRONMENTAL CONTAMINATION WITH L. MONOCYTOGENES REPRESENTS A SERIOUS RISK FOR SEVERAL COMMODITIES SUCH AS DAIRY FOODS, FRESH PRODUCE AND FROZEN FOODS AS THIS BACTERIUM IS CAPABLE OF WIDESPREAD CONTAMINATION OF EQUIPMENT AND FACILITIES FOR PACKING AND PROCESSING. S. ENTERICA IS A FOODBORNE PATHOGEN OF CONCERN IN LOW MOISTURE FOODS, POULTRY, MEAT AND PRODUCE AND IS CAPABLE OF PERSISTING ON FOOD CONTACT SURFACES.THE USE OF A DYNAMIC AND HARMLESS LIGHT TECHNOLOGY DURING DOWN TIME AND CLOSE OF OPERATION COULD SERVE AS A USEFUL TOOL IN PREVENTING BIOFILM FORMATION AND PERSISTENCE. ANTIMICROBIAL BLUE LIGHT (ABL) TECHNOLOGY HAS BEEN EXPLORED FOR HOSPITAL DISINFECTION WITH VERY PROMISING RESULTS, BUT ITS APPLICATION TO CONTROL FOODBORNE PATHOGENS REMAINS RELATIVELY LIMITED.THE GOAL OF THIS PROJECT IS TO INVESTIGATE THE APPLICATION OF ABL FOR REDUCING THE SURFACE VIABILITY OF LISTERIA MONOCYTOGENES AND SALMONELLA ENTERICA BIOFILMS, AND OF FOODBORNE ASSOCIATED VIRUSES. SPECIFICALLY, THIS PROJECT WILL: 1) DETERMINE OPTIMAL ABL EMISSION DOSES TO INACTIVATE L. MONOCYTOGENES AND SALMONELLA BIOFILMS AS SINGLE SPECIES ON INERT SOLID SURFACES; 2) ASSESS THE IMPACT OF MIXED CULTURE BIOFILMS ON ABL EFFECTIVENESS TO KILL PATHOGENIC BACTEIRA; 3) DETERMINE OPTIMAL CONDITIONS TO INACTIVATE NOROVIRUS, HEPATITIS A VIRUS AND SARS-COV-2; AND 4) CHARACTERIZE THE POSSIBLE INTERACTION OF ABL WITH SANITIZERS TO INACTIVATEPATHOGEN BIOFILMS. THIS PROJECT WILL INCLUDE A SERIES OF LABORATORY EXPERIMENTS IN WHICH DIFFERENT SURFACES WILL BE INOCULATED WITH PATHOGENIC BACTERIA BIOFILMS AND VIRUSES, ABL-TREATED USING DIFFERENT CONDITIONS AND THE EFFECTIVENESS WILL BE MEASURED BY A COMBINATION OF VIABILITY DETERMINATION AND MICROSCOPY OBSERVATIONS.
$599,900University Of Georgia Research Foundation, Inc. · · FY2022 · National Institute of Food and Agriculture
Drug Abuse, Incarceration & Health Disparities in HIV/AIDS: A Longitudinal Study
$599,895Linda A Teplin · Northwestern University At Chicago · R01 · FY2010 · DA
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)
$599,884Patrice Mimche · University Of Utah · R01 · FY2021 · DK
Role of Retinoid X Receptor Alpha in regulating PCSK9 transcription in the liver
$599,835Qing Miao · New York University D/B/A Nyu Long Island School Of Medicine · R01 · FY2024 · DK
HBV Prevention for Homeless at Risk for HBV/HCV/HIV
$599,827Adeline M Nyamathi · University Of California Los Angeles · R01 · FY2012 · DA
A Novel Druggable Epigenetic Vulnerability Pathway in HCC
$599,752Michael R Green · Univ Of Massachusetts Med Sch Worcester · R01 · FY2018 · CA
Opiate Dependence: Combined Naltrexone/Behavior Therapy
$599,707Edward V Nunes · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · R01 · FY2006 · DA
Engineering immunotherapeutic probiotics to mitigate irAE
$599,683Tal Danino · Columbia Univ New York Morningside · U01 · FY2023 · CA
Vaccine and Treatment Evaluation Unit: Phase I Clinical Trial to Evaluate a Hepatitis E Vaccine
$599,552Mark Joseph Mulligan · Emory University · N01 · FY2019 · AI